1Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices
Section snippets
What should physicians assess, and why?
Most physicians are aware of the 11 revised classification criteria for SLE of the American College of Rheumatology (ACR).1 (Table 1) A patient has to have four or more of these criteria to be classified as having SLE. These classification criteria are not diagnostic criteria; they were developed for research purposes to provide some attempt at standardisation for entry into clinical trials or outcome studies. The criteria do not have to be present simultaneously but can be cumulative over a
The disease activity indices
There is no gold standard for measuring disease activity in lupus and the physicians' visual analogue scale is not reliable in practice.19, 20 Although the physician's opinion is often considered the ‘gold standard’ for the evaluation of disease activity, it is evident that there is bias based on personal experience and different opinions on the relative merits of disease activity in different systems.20 Thus, an experience-based evaluation of activity cannot allow comparisons of data because
Assessment of damage
The treatment of lupus has improved. Fewer patients are dying early in their disease than 20–30 years ago.67 However, more patients are dying of the complications of lupus and the co-morbidities associated with lupus later in life, such as premature coronary and cerebrovascular disease67, 68. These complications are also causing increasing morbidity in lupus patients, at a time when the disease activity has usually been controlled by immunosuppressive therapy.
A group of investigators interested
Assessment of quality of life
From the patient's perspective it is important to consider health status/quality of life when assessing patients with lupus. To date, generic health status questionnaires have been used to formally assess the health-related quality of life of patients with lupus. The Short Form 36 (SF-36) has been most widely used.47 It covers eight domains assessing physical function, social function, role limitation due to physical or emotional factors, mental health, vitality, pain and general health
Summary
The assessment of a lupus patient is complex and requires a holistic approach. Disease activity, damage, health-related quality of life and the prevention of complications, including drug side effects, should be included in the assessment. With the development of new drugs and the need of controlled randomised studies, the evaluation of disease activity has become of paramount importance to select candidate patients for trials and to assess drug efficacy. Assessment of disease activity is also
References (90)
- et al.
Lupus and zoster
Lancet
(2003) - et al.
Systemic lupus erythematosus
Lancet
(2001) - et al.
Premature atherosclerosis in systemic lupus erythematosus
Rheumatics Disease Clinics of North America
(2000) The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort
Thrombosis Research
(2004)- et al.
Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians
Journal of Clinical Epidemiology
(2002) - et al.
The bimodal mortality pattern of systemic lupus erythematosus
American Journal of Medicine
(1976) - et al.
Measures of disease activity and damage in SLE Baillieres
Clinical Rheumatology
(1998) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
Arthritis and Rheumatism
(1997)The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes
Arthritis and Rheumatism
(1999)- et al.
Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group
Arthritis and Rheumatism
(2001)
Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus
Annals of the Rheumatic Diseases
Inability of community-based laboratories to identify pathological casts in urine samples
Archives of Pediatrics & Adolescent Medicine
Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes
British Medical Journal
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation modification of diet in renal disease study Group
Annals of Internal Medicine
The dissociation of arterial hypertension and lupus glomerulonephritis in systemic lupus erythematosus
Blood Press
C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study
The Journal of Rheumatology
Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective
Scandinavian Journal of Rheumatology
Long-term complications of systemic lupus erythematosus
Rheumatology (Oxford)
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study
American Journal of Epidemiology
Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data
Arthritis and Rheumatology
Prevalence and predictors of fragility fractures in systemic lupus erythematosus
Annals of the Rheumatic Diseases
Criteria for assessing disease activity in systemic lupus erythematosus
The Journal of Rheumatology
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group
The Journal of Rheumatology
Development and assessment of a computerised index of clinical disease activity in systemic lupus erythematosus Members of the British Isles Lupus Assessment Group (BILAG)
Quarterly Journal of Nuclear Medicine
Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus
Arthritis and Rheumatology
Definition, incidence, and clinical description of flare in systemic lupus erythematosus a prospective cohort study
Arthritis and Rheumatism
Validity and reliability of lupus activity measures in the routine clinic setting
The Journal of Rheumatology
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE
Arthritis and Rheumatism
Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE
Clinical and Experimental Rheumatology
Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE
Clinical and Experimental Rheumatology
Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus
The Journal of Rheumatology
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
Quarterlt Journal of Medicine
Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus
Annals of the Rheumatic Diseases
The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus
Lupus
Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation
The Journal of Rheumatology
Do lupus disease activity measures detect clinically important change?
The Journal of Rheumatology
Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus
The Journal of Rheumatology
Sensitivity of the systemic lupus erythematosus disease activity index. British isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus
Arthritis and Rheumatism
European consensus lupus activity measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus
Arthritis and Rheumatism
Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus
Arthritis and Rheumatism
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus
Arthritis and Rheumatism
The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation
Annals of the Rheumatic Diseases
From BILAG to BLIPS to BLIPS—disease activity assessment in lupus past, present and future
Lupus
The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view
British Journal of Rheumatology
Definition and treatment of lupus flares measured by the BILAG index
Rheumatology (Oxford)
Cited by (261)
Metabolic syndrome in systemic lupus erythematosus patients under Mediterranean diet
2024, Medicina ClinicaWhat is the best instrument to measure disease activity in SLE? – SLE-DAS vs Easy BILAG
2023, Autoimmunity ReviewsLow heterozygosity for rs3811050, a 5 prime untranslated region variant of the gene encoding interleukin-38 (IL1F10), is associated with a reduced risk of systemic lupus erythematosus
2024, Egyptian Journal of Medical Human Genetics